Clinical impact of using [ 18 F ] AlF ‐ NOTA ‐octreotide PET / CT instead of [ 68 Ga ]Ga‐ DOTA ‐ SSA PET / CT : Secondary endpoint analysis of a multicenter, prospective trial
Journal of Neuroendocrinology · 2024-08 · 36 (8)
DOI: 10.1111/jne.13420 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neuroendocrinology, online erschienen am 04.06.2024. Verfasst von Hannes Leupe und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging and Pathology, Nuclear Medicine, University Hospitals Leuven & Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgi…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
[ 18 F]AlF‐NOTA‐octreotide ([ 18 F]AlF‐OC) is a promising alternative for [ 68 Ga]Ga‐DOTA‐somatostatin analogs (SSAs) in positron emission tomography (PET) imaging of the somatostatin receptor (SSTR). Our aim is to assess changes in TNM staging and differences in patient management between [ 18 F]AlF‐OC PET/CT and [ 68 Ga]Ga‐DOTA‐SSA PET/CT in the work‐up of neuroendocrine tumor (NET) patients. Patients who underwent both [ 18 F]AlF‐OC and [ 68 Ga]Ga‐DOTA‐TATE or [ 68 Ga]Ga‐DOTA‐NOC PET/CT in our multicenter study (Pauwels et al., J Nucl Med .2023;63:632–638) with a NET were included for analysis. TNM staging was determined and compared for both tracers. For each patient, the blinded [ 68 Ga]Ga‐DOTA‐SSA or [ 18 F]AlF‐OC PET/CT images were presented in random order at a multidisciplinary team board. The images were presented together with clinical information and compared with previous SSTR and [ 18 F]FDG PET/CT imaging. After a consensus decision for patient management was recorded, the board was presented with the PET/CT images from the other SSTR tracer and a decision was made for the second tracer. Differences in management were classified as major if it entailed an intermodality change and minor if it led to an intramodality change. Compared with [ 68 Ga]Ga‐DOTA‐SSA, the use of [ 18 F]AlF‐OC led to a change in 16/75 patients: TNM staging changes in 10/75 patients (13.3%; downstaging in 3/10, upstaging in 7/10) and differences in clinical management were seen in 10/75 patients (13.3%), leading to a major difference in 7/10 cases and a minor change in 3/10 cases. All 10 cases with a difference in patient management between both PET tracers were caused by additional lesion detection by [ 18 F]AlF‐OC. The use of [ 18 F]AlF‐OC did not impact TNM staging or clinical management in the large majority of the patients (86.7%), further validating the potential for routine clinical use of [ 18 F]AlF‐OC PET/CT as an alternative for [ 68 Ga]Ga‐DOTA‐SSA PET/CT. The trial is registered under ClinicalTrials.gov identifier NCT04552847 and EudraCT 2020–000549‐15.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Imaging and Pathology, Nuclear Medicine, University Hospitals Leuven & Nuclear Medicine and Molecular Imaging, KU Leuven, Leuven, Belgium.
- Center for Oncological Research (CORE), Integrated Personalized and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium.
- Department of Oncology, Antwerp University Hospital & NETwerk Antwerpen-Waasland CoE, Edegem, Belgium.
- Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
- Digestive Oncology, University Hospitals Leuven, Leuven, Belgium.
- Department of Visceral Surgery, University Hospitals Leuven, Leuven, Belgium.
ORCID-Profile: Hannes Leupe, Johannes Hofland, Christophe M Deroose
Zitieren
APA
Leupe, H., Pauwels, E., Vandamme, T., Van den Broeck, B., Lybaert, W., Dekervel, J., Van Herpe, F., Jaekers, J., Cleeren, F., Hofland, J., Brouwers, A., Koole, M., Bormans, G., Van Cutsem, E., Geboes, K., Laenen, A., Verslype, C., Stroobants, S., & Deroose, C. M. (2024). Clinical impact of using [ 18 F ] AlF ‐ NOTA ‐octreotide PET / CT instead of [ 68 Ga ]Ga‐ DOTA ‐ SSA PET / CT : Secondary endpoint analysis of a multicenter, prospective trial. Journal of Neuroendocrinology, 36(8). https://doi.org/10.1111/jne.13420
Vancouver
Leupe H, Pauwels E, Vandamme T, Van den Broeck B, Lybaert W, Dekervel J, et al. Clinical impact of using [ 18 F ] AlF ‐ NOTA ‐octreotide PET / CT instead of [ 68 Ga ]Ga‐ DOTA ‐ SSA PET / CT : Secondary endpoint analysis of a multicenter, prospective trial. Journal of Neuroendocrinology. 2024;36(8). doi:10.1111/jne.13420
BibTeX
@article{Leupe2024,
author = {Leupe, Hannes and Pauwels, Elin and Vandamme, Timon and Van den Broeck, Bliede and Lybaert, Willem and Dekervel, Jeroen and Van Herpe, Filip and Jaekers, Joris and Cleeren, Frederik and Hofland, Johannes and Brouwers, Adrienne and Koole, Michel and Bormans, Guy and Van Cutsem, Eric and Geboes, Karen and Laenen, Annouschka and Verslype, Chris and Stroobants, Sigrid and Deroose, Christophe M},
title = {Clinical impact of using [ 18 F ] AlF ‐ NOTA ‐octreotide PET / CT instead of [ 68 Ga ]Ga‐ DOTA ‐ SSA PET / CT : Secondary endpoint analysis of a multicenter, prospective trial},
journal = {Journal of Neuroendocrinology},
year = {2024},
volume = {36},
number = {8},
doi = {10.1111/jne.13420}
}
EUVIMED